Merger and accounting scandals hit sector

Fernando Luque 20 August, 2002 | 3:04PM
Facebook Twitter LinkedIn
After losing 11.2% (in euros) during June, the MSCI Healthcare index registered a better than average return in July when it fell by 4.1% compared with a loss of 7.1% for the MSCI World index.

Investor sentiment

Financial scandals are not exclusively affecting the technology or telecoms sector. Some large biotech and pharmaceutical companies – such as Bristol Myers, ImClone and Merck - have also been accused of accounting irregularities. Merck in particular has acknowledged booking $14.1 billion (£9.2 billion) in revenue it did not receive during the last three years.

The other news that

affected the sector in recent weeks was the announcement by Pfizer that it will acquire Pharmacia for $60 billion in shares - which represents a premium of nearly 40% over Pharmacia’s share price. With this merger Pfizer will be the largest drug maker in the world with 11% of global market share. The day after the announcement Pfizer’s share price dropped by more than 15%.

Outlook

Even if the sector fundamentals – such as an ageing population and the need for new drugs - continue to support the case for long term growth, it is increasingly clear that the sector will remain under pressure. Increasing generic competition and the slower development of new drugs should have a substantial impact in the near future. The result of all this is that industry earnings may decline for the first time in a decade.

Apart from this there is also the risk that, as the global economy recovers, investors will shift into more cyclical sectors and away from defensive areas such as healthcare.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Fernando Luque

Fernando Luque  is Senior Financial Editor at Morningstar Spain 

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures